Pharmaceutical sponsor
Grit Biotechnology Clinical Trials
Studies where Grit Biotechnology is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 18Hematological Malignancy (Leukemia- Lymphoma)
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in…
- Trial name
- NCT06948981
- Testing
- GT719 Injection
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Grit Biotechnology
Autoimmune Diseases
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases.
- Trial name
- NCT07122076
- Testing
- GT719 Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Grit Biotechnology
Solid Tumors, Adult
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, lymphodepleting chemotherapy period, treatment and observation period, and follow-up…
- Trial name
- NCT05430373
- Testing
- GT101
- Where
- 5 sites in China
- Volunteers
- 31 people
- Sponsor
- Grit Biotechnology
Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
This is a single-arm, open-label, dose-escalation, prospective exploratory clinical study intended to evaluate the safety, efficacy and cellular pharmacokinetics of GT737 cells in adult patients with relapsed/refractory acute…
- Trial name
- NCT07676006
- Testing
- GT737 Injection
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Grit Biotechnology
IgA Nephropathy (IgAN), Membranous Nephropathy
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
This study is a single-arm, open-label, dose-escalation and dose-expansion clinical trial, divided into two phases: the first phase is the dose-escalation phase, and the second phase is the dose-expansion phase.
- Conditions
- IgA Nephropathy (IgAN), Membranous Nephropathy, ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN), Refractory Podocytopathy
- Trial name
- NCT07389499
- Testing
- CD19-targeted iNKT Cell Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Grit Biotechnology
Neurological Autoimmune Diseases
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in…
- Trial name
- NCT07021209
- Testing
- GT719 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Grit Biotechnology
Advanced Solid Tumors
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
This is a multicenter Phase I/II clinical trial. It aims to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of GT201 in patients with advanced solid tumors.
- Trial name
- NCT06144671
- Testing
- GT201, IL-2, PD-1 inhibitor
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Grit Biotechnology
B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL)
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia.
- Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
- Trial name
- NCT07205315
- Testing
- GT801 Injection
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Grit Biotechnology
Moderate to Severe Refractory Autoimmune Disease
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases
This is a single-arm, open-label, dose-escalation and dose-expansion clinical trial designed to evaluate the safety, efficacy, and cellular metabolism kinetics of GT801 in the treatment of moderate-to-severe refractory autoimmune…
- Trial name
- NCT07333118
- Testing
- GT801 Injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Grit Biotechnology
HNSCC
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for the treatment of advanced head and neck tumor subjects with safety…
- Trial name
- NCT06190275
- Testing
- GT201 in combination with PD-1 inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Grit Biotechnology